vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Morningstar, Inc. (MORN). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $644.8M, roughly 1.5× Morningstar, Inc.). On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 10.8%). Morningstar, Inc. produced more free cash flow last quarter ($53.6M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 6.2%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Morningstar, Inc. is an American financial services firm headquartered in Chicago, Illinois, founded by Joe Mansueto in 1984. It provides an array of investment research and investment management services.

ASTH vs MORN — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.5× larger
ASTH
$950.5M
$644.8M
MORN
Growing faster (revenue YoY)
ASTH
ASTH
+32.1% gap
ASTH
42.9%
10.8%
MORN
More free cash flow
MORN
MORN
$59.5M more FCF
MORN
$53.6M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
6.2%
MORN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASTH
ASTH
MORN
MORN
Revenue
$950.5M
$644.8M
Net Profit
$6.6M
Gross Margin
62.9%
Operating Margin
1.9%
24.2%
Net Margin
0.7%
Revenue YoY
42.9%
10.8%
Net Profit YoY
184.4%
EPS (diluted)
$0.12
$2.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
MORN
MORN
Q1 26
$644.8M
Q4 25
$950.5M
$641.1M
Q3 25
$956.0M
$617.4M
Q2 25
$654.8M
$605.1M
Q1 25
$620.4M
$581.9M
Q4 24
$665.2M
$591.0M
Q3 24
$478.7M
$569.4M
Q2 24
$486.3M
$571.9M
Net Profit
ASTH
ASTH
MORN
MORN
Q1 26
Q4 25
$6.6M
$115.1M
Q3 25
$373.0K
$91.6M
Q2 25
$9.4M
$89.0M
Q1 25
$6.7M
$78.5M
Q4 24
$-7.8M
$116.9M
Q3 24
$16.1M
$119.7M
Q2 24
$19.2M
$69.1M
Gross Margin
ASTH
ASTH
MORN
MORN
Q1 26
62.9%
Q4 25
61.1%
Q3 25
60.9%
Q2 25
61.9%
Q1 25
60.2%
Q4 24
60.7%
Q3 24
60.9%
Q2 24
61.1%
Operating Margin
ASTH
ASTH
MORN
MORN
Q1 26
24.2%
Q4 25
1.9%
24.9%
Q3 25
2.0%
20.7%
Q2 25
3.1%
20.7%
Q1 25
3.3%
19.6%
Q4 24
0.1%
28.5%
Q3 24
5.9%
20.3%
Q2 24
6.2%
19.0%
Net Margin
ASTH
ASTH
MORN
MORN
Q1 26
Q4 25
0.7%
18.0%
Q3 25
0.0%
14.8%
Q2 25
1.4%
14.7%
Q1 25
1.1%
13.5%
Q4 24
-1.2%
19.8%
Q3 24
3.4%
21.0%
Q2 24
3.9%
12.1%
EPS (diluted)
ASTH
ASTH
MORN
MORN
Q1 26
$2.73
Q4 25
$0.12
$2.79
Q3 25
$0.01
$2.17
Q2 25
$0.19
$2.09
Q1 25
$0.14
$1.82
Q4 24
$-0.14
$2.72
Q3 24
$0.33
$2.77
Q2 24
$0.40
$1.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
MORN
MORN
Cash + ST InvestmentsLiquidity on hand
$429.5M
$492.8M
Total DebtLower is stronger
$1.7B
Stockholders' EquityBook value
$779.3M
$1.0B
Total Assets
$2.2B
$4.0B
Debt / EquityLower = less leverage
1.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
MORN
MORN
Q1 26
$492.8M
Q4 25
$429.5M
$528.7M
Q3 25
$463.4M
$40.3M
Q2 25
$342.1M
$38.1M
Q1 25
$260.9M
$47.7M
Q4 24
$290.8M
$551.0M
Q3 24
$350.3M
$48.8M
Q2 24
$327.7M
$48.0M
Total Debt
ASTH
ASTH
MORN
MORN
Q1 26
$1.7B
Q4 25
Q3 25
$848.9M
Q2 25
$838.8M
Q1 25
$803.7M
Q4 24
$698.6M
Q3 24
$864.7M
Q2 24
$899.6M
Stockholders' Equity
ASTH
ASTH
MORN
MORN
Q1 26
$1.0B
Q4 25
$779.3M
$1.2B
Q3 25
$775.5M
$1.5B
Q2 25
$765.5M
$1.6B
Q1 25
$745.4M
$1.6B
Q4 24
$712.7M
$1.6B
Q3 24
$704.6M
$1.6B
Q2 24
$678.9M
$1.4B
Total Assets
ASTH
ASTH
MORN
MORN
Q1 26
$4.0B
Q4 25
$2.2B
$3.6B
Q3 25
$2.2B
$3.6B
Q2 25
$1.4B
$3.6B
Q1 25
$1.3B
$3.6B
Q4 24
$1.4B
$3.5B
Q3 24
$1.3B
$3.6B
Q2 24
$1.3B
$3.4B
Debt / Equity
ASTH
ASTH
MORN
MORN
Q1 26
1.68×
Q4 25
Q3 25
0.56×
Q2 25
0.52×
Q1 25
0.50×
Q4 24
0.43×
Q3 24
0.55×
Q2 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
MORN
MORN
Operating Cash FlowLast quarter
$-2.9M
Free Cash FlowOCF − Capex
$-6.0M
$53.6M
FCF MarginFCF / Revenue
-0.6%
8.3%
Capex IntensityCapex / Revenue
0.3%
5.9%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$437.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
MORN
MORN
Q1 26
Q4 25
$-2.9M
$204.0M
Q3 25
$10.0M
$195.7M
Q2 25
$90.9M
$99.0M
Q1 25
$16.6M
$91.0M
Q4 24
$-10.9M
$153.4M
Q3 24
$34.0M
$191.9M
Q2 24
$23.2M
$152.7M
Free Cash Flow
ASTH
ASTH
MORN
MORN
Q1 26
$53.6M
Q4 25
$-6.0M
$161.3M
Q3 25
$7.4M
$160.1M
Q2 25
$89.5M
$62.4M
Q1 25
$13.6M
$58.8M
Q4 24
$-13.5M
$112.8M
Q3 24
$31.7M
$155.8M
Q2 24
$20.4M
$120.8M
FCF Margin
ASTH
ASTH
MORN
MORN
Q1 26
8.3%
Q4 25
-0.6%
25.2%
Q3 25
0.8%
25.9%
Q2 25
13.7%
10.3%
Q1 25
2.2%
10.1%
Q4 24
-2.0%
19.1%
Q3 24
6.6%
27.4%
Q2 24
4.2%
21.1%
Capex Intensity
ASTH
ASTH
MORN
MORN
Q1 26
5.9%
Q4 25
0.3%
6.7%
Q3 25
0.3%
5.8%
Q2 25
0.2%
6.0%
Q1 25
0.5%
5.5%
Q4 24
0.4%
6.9%
Q3 24
0.5%
6.3%
Q2 24
0.6%
5.6%
Cash Conversion
ASTH
ASTH
MORN
MORN
Q1 26
Q4 25
-0.44×
1.77×
Q3 25
26.69×
2.14×
Q2 25
9.65×
1.11×
Q1 25
2.48×
1.16×
Q4 24
1.31×
Q3 24
2.11×
1.60×
Q2 24
1.21×
2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

MORN
MORN

Segment breakdown not available.

Related Comparisons